Heart Valve Devices – Market Insights – Europe

The European heart valve device market will continue to observe moderate growth, particularly due to growing demand for minimally invasive cardiac interventions boosting the adoption of THV devices. Positive clinical outcomes, along with favourable regulatory frameworks and evolving reimbursement policies, are facilitating faster market entry for new THV technologies.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for heart valve devices in Europe from 2019 through 2034.

The competitive landscape for the THV device market is evolving.

Which competitors have the most diverse portfolios in the heart valve device space?

How has the preference for transcatheter and surgical valve treatment shifted with recent clinical results and market conditions?

How are companies gaining competitive edge through mergers and acquisitions?

Novel THV technologies, including TTVI, TMVI and TTVR, will drive the expansion of European heart valve device market.

How will the approval of TTVR and TMVI devices impact the European heart valve devices market?

Which new THV devices are going to enter the market? How will they impact the market?

What’s the competitive landscape of the TMVR device space, with long-established MitraClip and emerging TMVR devices?

How will the TTVI market grow over the forecast period?

Clinical trial results play an important factor in the heart valve device market.

Which segments have been the most impacted by clinical results?

Which novel devices have been approved or have failed to gain approval due to data from clinical trials?

How will innovations currently being developed and evaluated in clinical trials affect changes in market share dynamics?

Market leaders in the European heart valve device market are consolidating or capturing sales and improving market shares by acquiring smaller competitors.

What effect have mergers and acquisitions had on this market?